Literature DB >> 8150340

Eradication of Helicobacter pylori with clarithromycin and omeprazole.

R P Logan1, P A Gummett, H D Schaufelberger, R R Greaves, G M Mendelson, M M Walker, P H Thomas, J H Baron, J J Misiewicz.   

Abstract

Clarithromycin, a new and well tolerated, acid stable macrolide antibiotic, has a similar antimicrobial spectrum to erythromycin but a better in vitro MIC90 (0.03 microgram/l-1) against Helicobacter pylori (H pylori). This study aimed at determining the eradication rate using clarithromycin 500 mg thrice daily and omeprazole 40 mg daily for two weeks. Patients were given an endoscopy and H pylori status assessed by antral culture (microaerobic conditions, for up to 10 days), antral and corpus histology tests (haematoxylin and eosin/Gimenez stains), and 13C-urea breath test (13C-UBT, European standard protocol, positive result = excess delta 13CO2 excretion > 5 per mil). Compliance was assessed by returned tablet counts. H pylori clearance at the end of treatment and eradication four weeks after finishing treatment were assessed by the 13C-UBT. Seventy three patients (54 men, median age 45 years) with duodenal ulcers (n = 42) or duodenitis/non-ulcer dyspepsia (n = 31) all with a positive 13C-UBT (mean (SEM) excess delta-13CO2 excretion = 26.6 (4.9) per mil) and either positive antral histology (n = 72) or positive antral culture (n = 35) were studied. Before treatment 2/27 (7%) isolates of H pylori were resistant to clarithromycin and five isolates were resistant to metronidazole. In 70/73 (96%) the 13C-UBT was negative immediately after finishing treatment. Four weeks later the 13C-UBT was negative in 57/73 (mean (SEM) excess delta 13CO2 excretion = 1.2 (0.3) per mil, eradication rate = 78%). Forty eight (66%) patients experienced a metallic taste while taking the tablets. Although four (5%) patients, however, could not complete the course of treatment, in only one of these four was H pylori not eradicated. These results show that duel therapy with clarithromycin and omeprazole is well tolerated. With an eradication rate of 78% it is an effective treatment for metronidazole resistant H pylori and may be an alternative to standard triple therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8150340      PMCID: PMC1374583          DOI: 10.1136/gut.35.3.323

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  14 in total

1.  Elimination of Helicobacter pylori under treatment with omeprazole.

Authors:  M Stolte; B Bethke
Journal:  Z Gastroenterol       Date:  1990-06       Impact factor: 2.000

2.  Metronidazole resistance in Helicobacter pylori.

Authors:  Y Glupczynski; A Burette; E De Koster; J F Nyst; M Deltenre; S Cadranel; L Bourdeaux; D De Vos
Journal:  Lancet       Date:  1990-04-21       Impact factor: 79.321

3.  Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori.

Authors:  B J Marshall; C S Goodwin; J R Warren; R Murray; E D Blincow; S J Blackbourn; M Phillips; T E Waters; C R Sanderson
Journal:  Lancet       Date:  1988 Dec 24-31       Impact factor: 79.321

4.  One week eradication regimen for Helicobacter pylori.

Authors:  R P Logan; P A Gummett; J J Misiewicz; Q N Karim; M M Walker; J H Baron
Journal:  Lancet       Date:  1991-11-16       Impact factor: 79.321

5.  Clarithromycin for the eradication of Helicobacter pylori.

Authors:  D Y Graham; A R Opekun; P D Klein
Journal:  J Clin Gastroenterol       Date:  1993-06       Impact factor: 3.062

6.  Cleaning and disinfection of equipment for gastrointestinal flexible endoscopy: interim recommendations of a Working Party of the British Society of Gastroenterology.

Authors: 
Journal:  Gut       Date:  1988-08       Impact factor: 23.059

7.  Short report: the effect of omeprazole on Helicobacter pylori and associated gastritis.

Authors:  M A Daw; P Deegan; E Leen; C O'Moráin
Journal:  Aliment Pharmacol Ther       Date:  1991-08       Impact factor: 8.171

8.  Enhancement of antibiotic concentrations in gastric mucosa by H2-receptor antagonist. Implications for treatment of Helicobacter pylori infections.

Authors:  T U Westblom; D E Duriex
Journal:  Dig Dis Sci       Date:  1991-01       Impact factor: 3.199

9.  Factors influencing the eradication of Helicobacter pylori with triple therapy.

Authors:  D Y Graham; G M Lew; H M Malaty; D G Evans; D J Evans; P D Klein; L C Alpert; R M Genta
Journal:  Gastroenterology       Date:  1992-02       Impact factor: 22.682

10.  Cure of duodenal ulcer associated with eradication of Helicobacter pylori.

Authors:  E A Rauws; G N Tytgat
Journal:  Lancet       Date:  1990-05-26       Impact factor: 79.321

View more
  34 in total

1.  Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole.

Authors:  Javier Afeltra; Roxana G Vitale; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

2.  Helicobacter pylori and duodenal ulcer: Guilty as charged.

Authors:  S Shafran; J Conly
Journal:  Can J Infect Dis       Date:  1994-11

3.  H pylori infection.

Authors:  P S Phull; M R Jacyna
Journal:  Br J Gen Pract       Date:  1996-01       Impact factor: 5.386

4.  The British Society of Gastroenterology Diamond Jubilee. March 1997.

Authors: 
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

5.  Treating Helicobacter pylori--the best is yet to come?

Authors:  A Harris; J J Misiewicz
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

6.  Use of PCR and culture to detect Helicobacter pylori in naturally infected cats following triple antimicrobial therapy.

Authors:  S E Perkins; L L Yan; Z Shen; A Hayward; J C Murphy; J G Fox
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

7.  Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: a multiple logistic regression analysis.

Authors:  H Miwa; H Misawa; T Yamada; A Nagahara; K Ohtaka; N Sato
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

Review 8.  Role of Helicobacter pylori in gastrointestinal disease: implications for primary care of a revolution in management of dyspepsia.

Authors:  B C Delaney
Journal:  Br J Gen Pract       Date:  1995-09       Impact factor: 5.386

9.  Helicobacter pylori and upper gastrointestinal disease: a survey of gastroenterologists in the United Kingdom.

Authors:  R Milne; R P Logan; D Harwood; J J Misiewicz; D Forman
Journal:  Gut       Date:  1995-09       Impact factor: 23.059

Review 10.  Peptic ulcers can now be cured without operation.

Authors:  J H Baron
Journal:  Ann R Coll Surg Engl       Date:  1995-05       Impact factor: 1.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.